Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma

This study has been completed.
Information provided by:
Teva Branded Pharmaceutical Products, R&D Inc. Identifier:
First received: June 14, 2004
Last updated: June 23, 2005
Last verified: October 2004

This study is designed to examine the effectiveness of two bronchodilator inhalers in patients who have exercise- induced asthma

Condition Intervention Phase
Exercise-Induced Asthma
Drug: Bronchodilator
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Single-Dose Effectiveness Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma

Resource links provided by NLM:

Further study details as provided by Teva Branded Pharmaceutical Products, R&D Inc.:

Study Start Date: June 2004

Ages Eligible for Study:   12 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Demonstrable exercise-induced asthma, with or without asthma (predicted FEV1 70% or higher prior to exercise challenge);
  • No contraindications for exercising maximally

Exclusion Criteria:

  • Continuous requirement for beta-blockers, MAO inhibitors, tricyclic antidepressants, long-acting inhaled beta-agonists, antileukotrienes and/or cromones, steroids other than those inhaled
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00085774

United States, Colorado
Colorado Allergy and Asthma Centers, PC
Denver, Colorado, United States, 80230
Colorado Allergy and Asthma Centers, PC
Englewood, Colorado, United States, 80112
Colorado Allergy and Asthma Centers, PC
Lakewood, Colorado, United States, 80401
Sponsors and Collaborators
Teva Branded Pharmaceutical Products, R&D Inc.
  More Information

No publications provided Identifier: NCT00085774     History of Changes
Other Study ID Numbers: IXR-302-4-167
Study First Received: June 14, 2004
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Asthma, Exercise-Induced
Bronchial Diseases
Hypersensitivity, Immediate
Immune System Diseases
Respiratory Hypersensitivity
Respiratory Tract Diseases
Bronchodilator Agents
Anti-Asthmatic Agents
Autonomic Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses processed this record on March 03, 2015